Pharmacokinetic bioequivalence crossover study of branded generic and innovator formulations of the cholesterol lowering agent ezetimibe

This publication has 9 references indexed in Scilit:

• Ezetimibe – a new approach in hypercholesterolemia management
  Pharmacological Reports, 2011
• Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects
  European Journal of Clinical Pharmacology, 2010
• Complex Pharmacokinetic Behavior of Ezetimibe Depends on Abcc2, Abcc3, and Abcg2
  Drug Metabolism and Disposition, 2009
• Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post‐marketing clinical study on healthy volunteers
  British Journal of Clinical Pharmacology, 2009
• Niemann–Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter
  Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
• The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
  Proceedings of the National Academy of Sciences, 2005
• The Discovery of Ezetimibe: A View from Outside the Receptor
  Journal of Medicinal Chemistry, 2003
• Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects
  Drug Metabolism and Disposition, 2002
• A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
  Clinical Therapeutics, 2001